Aptorum Group names Laura Philips as a new board member.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2025
0mins
New Board Appointment: Laura Philips has been appointed as an independent director to the board of Aptorum Group following its merger with DiamiR Biosciences Corp.
Merger Details: The all-stock merger transaction, announced on July 16, 2025, is expected to close in the fourth quarter of 2025, pending stockholder approval and customary closing conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APM
About APM
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Andean Precious Metals Corp. Raises C$83.1M by Selling 7.9M Shares at C$10.50 Each
- Share Issuance Plan: Andean Precious Metals Corp. has entered into an agreement with PMB Partners to sell 7.9 million common shares at C$10.50 each, raising a total of C$83.1 million, aimed at enhancing interest from institutional investors and improving liquidity.
- Shareholder Ownership Changes: Following the offering, founder Alberto Morales's ownership will decrease from 53.22% to 47.94%, yet he will remain the largest shareholder, demonstrating a continued commitment to the company's long-term strategy.
- Market Access Strategy: The offering will be publicly issued in all Canadian provinces via a prospectus supplement and may be offered to qualified institutional buyers in the U.S., indicating the company's proactive strategy in expanding market reach and attracting new investors.
- Liquidity Enhancement Commitment: Andean Precious Metals has committed not to issue new shares for 90 days post-offering to avoid shareholder dilution, thereby enhancing market trading liquidity and boosting investor confidence.
Continue Reading
Andean Precious Metals Corp. Completes C$83.1 Million Secondary Offering
- Offering Overview: Andean Precious Metals Corp. has entered into an agreement with PMB Partners to sell 7.915 million common shares at C$10.50 each, generating gross proceeds of C$83.1 million, aimed at enhancing institutional investor interest and improving liquidity.
- Shareholder Ownership Changes: Following the offering, founder Alberto Morales's ownership will decrease from 53.22% to 47.94%, yet he will remain the largest shareholder, reflecting his ongoing commitment to the company's strategic vision.
- Liquidity Enhancement: This secondary offering allows Andean to avoid shareholder dilution while increasing the public float, which is expected to improve trading liquidity and attract new investors.
- Future Outlook: The offering is anticipated to close on January 28, 2026, subject to necessary corporate and regulatory approvals, further supporting the company's long-term growth strategy and market expansion plans.
Continue Reading